Sequoia Financial Advisors LLC raised its holdings in Amgen, Inc. (NASDAQ:AMGN) by 17.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,293 shares of the medical research company’s stock after buying an additional 1,412 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Amgen were worth $1,884,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of AMGN. Savior LLC acquired a new position in Amgen in the fourth quarter valued at approximately $34,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Amgen by 830.4% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,042 shares of the medical research company’s stock valued at $251,000 after buying an additional 930 shares during the period. Davis R M Inc. lifted its stake in Amgen by 5.6% in the fourth quarter. Davis R M Inc. now owns 7,322 shares of the medical research company’s stock valued at $1,765,000 after buying an additional 386 shares during the period. Global Retirement Partners LLC lifted its stake in Amgen by 4.6% in the fourth quarter. Global Retirement Partners LLC now owns 2,573 shares of the medical research company’s stock valued at $620,000 after buying an additional 112 shares during the period. Finally, J.W. Cole Advisors Inc. acquired a new position in Amgen in the fourth quarter valued at approximately $1,275,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:AMGN traded up $1.65 during trading on Friday, reaching $226.43. The company’s stock had a trading volume of 2,305,494 shares, compared to its average volume of 2,887,619. The firm has a market cap of $132.23 billion, a price-to-earnings ratio of 17.75, a price-to-earnings-growth ratio of 1.92 and a beta of 0.97. The company has a debt-to-equity ratio of 3.16, a quick ratio of 1.28 and a current ratio of 1.59. The firm has a 50 day moving average of $228.36 and a 200-day moving average of $225.14. Amgen, Inc. has a 12 month low of $166.68 and a 12 month high of $244.99.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.70 by $0.47. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.56 EPS. Equities research analysts forecast that Amgen, Inc. will post 15.58 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 8th. Shareholders of record on Monday, May 18th will be paid a $1.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.40 dividend on an annualized basis and a yield of 2.83%. Amgen’s dividend payout ratio (DPR) is presently 43.18%.
A number of brokerages have recently weighed in on AMGN. Argus reaffirmed a “buy” rating and set a $265.00 target price on shares of Amgen in a research report on Thursday, February 6th. Mizuho reaffirmed a “hold” rating and set a $215.00 target price on shares of Amgen in a research report on Thursday, April 30th. Credit Suisse Group reaffirmed a “buy” rating and set a $252.00 target price on shares of Amgen in a research report on Sunday, February 2nd. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Cowen reaffirmed a “buy” rating on shares of Amgen in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seventeen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $244.65.
In other news, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $229.27, for a total transaction of $229,270.00. Following the completion of the transaction, the director now owns 16,482 shares in the company, valued at approximately $3,778,828.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $237.31, for a total value of $100,856.75. Following the transaction, the director now owns 5,834 shares of the company’s stock, valued at approximately $1,384,466.54. The disclosure for this sale can be found here. Insiders sold a total of 2,425 shares of company stock valued at $563,477 in the last 90 days. Corporate insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: Initial Public Offering (IPO)
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.